StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin Pharma (BMRN) Announces Positive Preclinical Data from BMN 270 Phase 1/2 in Hemophilia A
April 20, 2016 8:31 AM
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
BioMarin Pharma (BMRN) Announces Enrollment of First BMN 250 Phase 1/2 Patient for MPS IIIB
April 21, 2016 4:34 PM
BioMarin Pharma (BMRN) Updates on Vosoritide Phase 2 in Achondroplasia; Evidence of Durability Noted
April 20, 2016 10:40 AM
BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
April 20, 2016 8:30 AM
